P J Hoskin1, A M Rojas2, S N Peiris1, V Mullassery1, I Y Chong1. 1. Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, UK. 2. Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, UK. Electronic address: arc03@btconnect.com.
Abstract
AIMS: To evaluate pre-treatment haemoglobin and peripheral blood lymphocyte (PBL) counts as predictors of treatment outcome in cervix carcinoma treated with radical chemoradiation. MATERIALS AND METHODS: Pre-treatment PBL counts and haemoglobin concentrations were retrieved from full blood count examinations from 111 patients who received concurrent chemoradiotherapy. Overall survival and relapse-free survival were obtained using the Kaplan-Meier method by ranking the data by median haemoglobin and PBL, singly and then in association. Their independence and significance as predictors of outcome were analysed using the Cox proportional hazard model. RESULTS: Survival rates were significantly higher in patients whose haemoglobin level or PBL counts were at or above the corresponding median value. At 5 years, rates of overall survival were 77% versus 41% (P = 0.0003) and 75% versus 42% (P = 0.002), when dichotomised around median haemoglobin and PBL, respectively. In multivariate and univariate analyses, both PBL and haemoglobin were independent and significant predictors for risk of death and relapse. Their predictive power was dramatically enhanced when the data were stratified into four groups by associating patients with haemoglobin ≥ median or < median with those whose PBL was ≥ or < median. CONCLUSION: Baseline PBL and haemoglobin seem to be strong, independent predictors of treatment outcome in carcinoma of the cervix, particularly if patient response is ranked using the predictors simultaneously. The hypothesis needs to be tested and, if confirmed, the markers should be used in combination to identify those at greater risk of failure who may benefit from additional therapy, with further validation in prospective trials offering treatment modification.
AIMS: To evaluate pre-treatment haemoglobin and peripheral blood lymphocyte (PBL) counts as predictors of treatment outcome in cervix carcinoma treated with radical chemoradiation. MATERIALS AND METHODS: Pre-treatment PBL counts and haemoglobin concentrations were retrieved from full blood count examinations from 111 patients who received concurrent chemoradiotherapy. Overall survival and relapse-free survival were obtained using the Kaplan-Meier method by ranking the data by median haemoglobin and PBL, singly and then in association. Their independence and significance as predictors of outcome were analysed using the Cox proportional hazard model. RESULTS: Survival rates were significantly higher in patients whose haemoglobin level or PBL counts were at or above the corresponding median value. At 5 years, rates of overall survival were 77% versus 41% (P = 0.0003) and 75% versus 42% (P = 0.002), when dichotomised around median haemoglobin and PBL, respectively. In multivariate and univariate analyses, both PBL and haemoglobin were independent and significant predictors for risk of death and relapse. Their predictive power was dramatically enhanced when the data were stratified into four groups by associating patients with haemoglobin ≥ median or < median with those whose PBL was ≥ or < median. CONCLUSION: Baseline PBL and haemoglobin seem to be strong, independent predictors of treatment outcome in carcinoma of the cervix, particularly if patient response is ranked using the predictors simultaneously. The hypothesis needs to be tested and, if confirmed, the markers should be used in combination to identify those at greater risk of failure who may benefit from additional therapy, with further validation in prospective trials offering treatment modification.
Authors: Sara E Beltrán Ponce; Beth A Erickson; William A Hall; Meena Bedi; Michael J Martens; Malika Siker; James Thomas; Ben George; Kirk Ludwig; Carrie Peterson; Timothy Ridolfi; John M Longo Journal: J Gastrointest Oncol Date: 2022-02
Authors: Casey W Williamson; Igor Sirák; Ronghui Xu; Lorraine Portelance; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Elena S Heide; Catheryn M Yashar; Michael T McHale; Walter Bosch; Jessica Lowenstein; Cheryl C Saenz; Steve Plaxe; Ramez Eskander; John Einck; Arno J Mundt; Jyoti Mayadev; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-20 Impact factor: 7.038
Authors: Emily S Wu; Titilope Oduyebo; Lauren P Cobb; Diana Cholakian; Xiangrong Kong; Amanda N Fader; Kimberly L Levinson; Edward J Tanner; Rebecca L Stone; Anna Piotrowski; Stuart Grossman; Kara Long Roche Journal: Gynecol Oncol Date: 2015-11-11 Impact factor: 5.482
Authors: H van Meir; R A Nout; M J P Welters; N M Loof; M L de Kam; J J van Ham; S Samuels; G G Kenter; A F Cohen; C J M Melief; J Burggraaf; M I E van Poelgeest; S H van der Burg Journal: Oncoimmunology Date: 2016-12-23 Impact factor: 8.110
Authors: David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin Journal: Cancer Med Date: 2021-06-12 Impact factor: 4.452